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Other names: CRAF; Raf-1; c-Raf 
Location: 3p25 
DNA/RNA 
Note: History and Nomenclature:  
c-Raf-1 was the first successfully cloned functional 
human homolog of the v-Raf gene, and thus the gene 
product of c-Raf-1 has historically been referred to in 
the literature simply as Raf-1. Subsequently, B-Raf and 
A-Raf-1 paralogues (BRAF, located in Xq13 and 
ARAF, located in Xp11) were discovered. A suitable 
nomenclature is as follows: A-RAF, B-RAF, and C-
RAF for the functional human proteins and A-RAF, B-
RAF, and C-RAF for the corresponding genes; a-raf, b-
raf, and c-raf for the murine proteins and A-Raf, B-Raf, 
and C-Raf for the corresponding genes. Raf-1 (or RAF-
1) is generally taken to mean C-RAF-1 but could apply 
to A-RAF-1 equally. Here, RAF-1 will be taken to 
mean C-RAF-1 (RAF-1 = C-RAF-1, etc.). 
Description 
C-RAF (RAF-1, C-RAF-1) encompasses 80,570 bp of 
DNA; 17 Exons. 
Transcription 




The RAF proteins share three conserved domains: two 
(CR1 and CR2) in the N terminus and a third (CR3-
encoding for the serine/threonine kinase domain) in the 
C terminus. The RAF proteins exhibit complex 
regulation involving numerous phosphorylation sites 
throughout the proteins. Despite constitutional 
similarity, the Raf isoforms have been shown to carry 
out non-redundant functions, implying that they are 
distinct. 
RAF-1 (C-RAF-1): 72-74 kDa. 
Note: A-RAF: about 68 kDa. 
Note: B-RAF (which undergoes alternate splicing): 
ranges from 75 to 100 kDa. 
Expression 
C-RAF (RAF-1) and A-RAF mRNA is expressed 
ubiquitously. A-RAF mRNA is highly expressed in 
urogenital organs. B-RAF is expressed in a wide range 




RAF proteins are part of the conserved MAPK 
(mitogen-activated protein kinase)/ERK (extracellular 
signal-regulated kinase) signaling cascade between th  
cell surface and the nucleus. RAF is regulated by the 
upstream RAS family of small G proteins. RAS is 
predominantly located on the inner leaflet of the plasma 
membrane and is functionally activated by GTP-
binding. Binding of various extracellular ligands such 
as growth factors and hormones activates RAS and 
subsequently RAF proteins. RAS binds directly to the
N-terminal regulatory domain or RAF (the RAS 
binding domain (RBD)). RAS interacts secondarily 
with the cysteine-rich domain (CRD) on CR1 of RAF. 
RAS-RAF binding can be affected by 14-3-3 proteins 
and other scaffold/adaptor proteins kinase suppresso  of 
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RAS (KSR), the multidomain protein connector-
enhancer of KSR (CNK), and the leucine-rich-repeat 
protein suppressor of RAS mutations-8 (SUR8), which 
cause formation of various homo- and heterodimers 
and subsequently affect signal transduction. RAF 
activation leads to activation of the protein kinases 
MEK1 and MEK2 and subsequently the MAPK 
proteins ERK1 and ERK2. The downstream effects of 
MEK1/2-ERK1/2 activation are varied, complex, and 
depend on the cellular context. Resultant effects 
include activation of transcription factors involved in 
tumorigenesis, cell growth, survival, differentiation, 
metabolism, and cytoskeletal rearrangements. RAF-1 
(C-RAF-1), A-RAF, and B-RAF are all capable of 
activating the MEK1/2-ERK1/2 signaling pathway. 
RAF-1 is capable of activating the NF-kB transcription 
factor through an unknown mechanism that does not 
seem to involve direct phosphorylation of NF-kB and is 
independent of MEK1/2-ERK1/2 signaling. 
RAF-1 is known to directly affect cell survival through 
phosphorylation of BAG1 (BCL2-associated 
athanogene-1), an anti-apoptotic protein that binds to 
BCL2, a second anti-apoptotic factor, also the 
prototype for a family of mammalian genes involved in 
mitochondrial outer membrane permeability (MOMP), 
thus restoring its function. BCL2 also targets RAF-1 to 
the mitochondrial membrane, where it is able to more 
readily phosphorylate substrates. The RAF-
1/BAG1/BCL2 interaction allows RAF-1 to 
phosphorylate the pro-apoptotic protein BAD at the 
mitochondrial membrane, promoting cell survival. 
Other known substrates of RAF-1 include the 
phosphatase CDC25C, the apoptosis signal-regulating 
kinase-1 (ASK1), and the tumor-suppressor protein 
retinoblastoma (Rb). 
RAF-1 is tightly regulated by the AKT/PKB pathway 
through phosphorylation at S259. 
Mutations 
Somatic 
It has been widely established that RAF-1 over activity, 
typically via ras-activating mutations, is central to
tumorigenesis and cell proliferation in numerous 
cancers (about 30% of all human cancers). However, it 
has come to the fore that oncogenesis may be due to 
ras/RAF-1 dysregulation (either increased or decreased 
expression) rather than increases in ras/RAF-1 activity 
exclusively. 
Implicated in 
Medullary Thyroid Cancer (MTC) 
Disease 
A neuroendocrine tumor derived from parafollicular C 
cells of the thyroid gland, MTC is the third most 
common form of thyroid cancer, accounting for 3-5% 
of all cases. MTC cells secrete hormones and tumor 
markers such as calcitonin, chromogranin A (CgA), 
and carcinoembryonic antigen (CEA). 
Symptoms are related to either direct invasion or 
metastasis (neck mass, dyspnea, dysphagia, voice 
changes, pain) or tumor secretion of bioactive amines 
and peptides (diarrhea, flushing). 
Prognosis 
Currently, surgery is the only potentially curative 
therapy for patients with MTC. The recommended 
operation is total thyroidectomy with lymph node 
dissection. However, 50% of patients treated with 
surgery suffer persistent or recurrent disease. 
Oncogenesis 
20% of patients with medullary thyroid cancer have n 
autosomal dominant inherited form of the disease, 
which is the result of well-characterized point 
mutations in the RET proto-oncogene. RAF-1 is 
conserved but not expressed at baseline in MTC. Pre-
clinical studies have shown that activation of RAF-1 in 
MTC (TT) cells by means of RAF-1 gene transfection 
or RAF-1 activating small molecules (ZM336372) 




Carcinoids are tumors that arise from the diffuse 
neuroendocrine cell system of the gut, lungs, and other 
organs. The incidence is 1-5 per 100,000 individuals. 
Carcinoids frequently metastasize to the liver and re 
the second most common source of isolated liver 
metastases. Carcinoids secrete various bioactive 
hormones such as 5-HT (5-hydroxy tryptophan, also 
known as serotonin) and chromogranin A. 
Prognosis 
Patients with hepatic metastases suffer debilitating 
symptoms such as abdominal pain, flushing, 
bronchoconstriction, and diarrhea. Palliative treatment 
for these hormone-induced symptoms includes 
somatostatin analogs (such as octeotride). Conventional 
anticancer treatments such as chemotherapy and 
external beam radiation are largely ineffective for 
carcinoid tumors. 
Oncogenesis 
RAF-1 activation is detrimental to tumorigenesis in 
carcinoid cells. Marked reduction in neuroendocrine 
phenotypic markers such as human achaete-scute 
complex like-1 (ASCL-1) and bioactive hormones 5-
HT, chromogranin A, and synaptophysin has been 
noted upon RAF-1 activation using an estrogen-
inducible RAF-1 construct in human GI (BON) and 
pulmonary carcinoid cell lines (NCI-H727). 
Treatment of GI carcinoid cells with RAF-1 activator 
ZM336372 led to a decrease in bioactive hormone 
levels, a suppression of cellular proliferation, an 
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increase in cell cycle inhibitors p21 and p18, as well as 
a decrease in the neuroendocrine phenotypic marker 
ASCL-1. ZM336372 treatments also led to progressive 
phosphorylation (activation) of MEK1/2, ERK1/2, and 
RAF-1. 
Small Cell Lung Cancer (SCLC) 
Disease 
SCLC tends to present with metastatic and regional 
spread. Carcinoids rarely metastasize, arise from major 
bronchi, and express neuron-specific enolase, 
chromogranin, and synaptophysin. Neuroendocrine 
carcinoids or atypical carcinoids have a more 
aggressive course. 
Oncogenesis 
Human small-cell lung cancer (SCLC) cell lines rarely 
harbor ras-activating mutations. In one cell line of 
SCLC, DMS53, it was shown that by RAF-1 induction 
using an estrogen-inducible RAF-1 construct SCLC 
cells underwent differentiation and G1-specific growth 
arrest in conjunction with MEK/ERK1/2 pathway 
activation. 
Non-Small Cell Lung Cancer (NSCLC) 
Disease 
Adenocarcinoma is the most common type of NSCLC 
accounting for about 40% of cases. Lesions are 
generally located peripherally and develop systemic 
metastases despite small primary tumors. 25% of 
NSCLC are squamous cell carcinomas which often 
remain localized. 
Oncogenesis 
RAF-1 is over-expressed due to oncogenic ras 
mutations in about 35% of NSCLC. 
The majority of NSCLC exhibits EGFR over-
expression leading to upregulation of RAF-1 activity. 
NSCLC has been shown to be mediated by a TGF-a 
/EGFR-mediated autocrine loop activated by signaling 
involving RAF-1 and PI3K-Akt. 
Pheochromocytoma 
Disease 
Pheochromocytomas are neuroectodermal in origin and 
arise from the chromaffin cells of the adrenal medulla. 
10% of tumors are bilateral. Typical symptoms such as 
hypertension, headaches, diaphoresis, palpitations, 
diarrhea, and skin rashes, are related to tumor 
production of catecholamines, especially in patients 
with metastases. Pheochromocytoma is potentially 
fatal, but relatively uncommon (2-8 cases per million 
people annually). Curative therapy is surgery, usually 
accomplished by laparoscopic adrenalectomy. 
Oncogenesis 
Activation of MEK1/2-ERK1/2 is necessary for 
differentiation of pheochromocytoma (PC12) cells and  
leads to decreased cell proliferation. RAF-1 activation 
in pheochromocytoma cells using ZM336372 led to 
cellular differentiation, growth arrest, and a decrease in 
the neuroendocrine marker chromogranin A. 
Non-Neuroendocrine Cancers with ras-
activating Mutations 
Oncogenesis 
About 30% of all human cancers express ras-activating 
mutations. More than 85% of pancreatic 
adenocarcinomas and 50% of colonic adenocarcinomas 
harbor K-ras mutations. K-ras is an upstream effector 
of RAF-1 in the RAF-1/MEK/ERK1/2 signaling 
pathway. Ras mutations have also been linked to 
tumorigenesis of cholangiocarcinoma, adenocarcinoma 
of the lung, squamous cell cancer, gastric 




RAF-1 is over-activated due to oncogenic ras mutations 
in about 50% of colon cancers. These mutations are 
associated with poor prognosis, and are necessary for 
maintenance of the malignant phenotype. 
RAF-1 inhibition in response to interaction with RAF 
kinase inhibitor protein (RKIP) (up-regulated in 
conjunction with the nuclear factor kappa B signalig 
pathway) has been linked with overall and disease-fre  
survival in patients with colorectal cancers. RKIP has 
been identified as potentially useful for identifying 
early-stage CRC patients at risk for relapse. 
Pancreatic Carcinoma 
Oncogenesis 
RAF-1 is overactivated due to oncogenic ras mutations 
in about 90% of pancreatic carcinomas (Panc-1 and 
Mia-PaCa2). It has been shown that malignancy of 
these cells is reduced using k-ras RNAi. 
Pharmacological inhibition of the RAF/MEK/ERK 
pathway in pancreatic cancer cell lines (via MEK 
inhibition) results in reduction in cellular proliferation 
and an increase in cell cycle arrest. 
Hepatocellular Carcinoma (HCC) 
Oncogenesis 
RAF-1 is over-activated in about 50% of biopsies while 
the RAF-1 protein is over-expressed in nearly 100% of 
all HCC's. Angiogenesis and other functions essential 
to tumorigenesis in HCC have been reported to depend 
on the RAF/MEK/ERK signaling pathway. RAF-1 
inhibitor Sorafenib has been reported (in-vitro and i -
vivo) to inhibit RAF-1 activity, leading to decreased 
MEK/ERK activity, reduced cellular proliferation, and 
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Prostate Cancer 
Oncogenesis 
RAF kinase inhibitor protein (RKIP) coding mRNAs 
have been observed to activate interferon-inducible 
2',5'-oligoadenylate synthetases (OAS). OAS activity is 
characteristically increased (via these mRNAs) in 
prostate cancer cell lines PC3, LNCaP and DU145. 
RKIP expression is detectable in primary prostate 
cancer sections but not in metastases. This suggests 
RKIP's characterization as an anti-metastasis gene 
using the RAF/MEK/ERK signaling pathway is 
appropriate. 
RAF-1 inhibition using systemically delivered novel 
cationic cardiolipin liposomes (NeoPhectin-AT) 
containing a small interfering RNA (siRNA) against 
RAF-1 causes tumor growth inhibition in a xenograft 
model of human prostate cancer. 
RAF/MEK/ERK signaling pathway activation via a 
biologically active peptide called a prosaptide (TX14A) 
stimulates cell proliferation/survival, migration, and 
invasion in human prostate cancer cells. 
NSC 95397 and NSC 672121, cdc25 inhibitors, were 
shown to activate the RAF/MEK/ERK pathway in 
prostate cancer cells. 
RAF-1 activation in LNCaP prostate cancer cells using 




Growth hormone releasing hormone (GHRH) has been 
shown to regulate breast cancer cell proliferation and 
differentiation. In MDA-231 breast cancer cells, 
exogenous GHRH stimulated dose-dependent 
proliferation. RAF-1 inhibition using the agent 
PD98059 caused prevention of MAPK phosphorylation 
by GHRH as well as reduced cellular proliferation. 
Proliferative effects of steroid hormone estradiol on
MCF-7 breast cancer cells have been linked with 
increased expression of RAF-1, possibly due to direct 
activation of RAF-1 by estradiol. 
RAF kinase inhibitor protein (RKIP) is associated with 
metastasis suppression. RKIP expression is lost in 
lymph node metastases. This suggests RKIP is a 
metastasis inhibitor gene and that RAF-1 expression 
enables metastasis. 
The PTK inhibitor AG 879 inhibits proliferation of 
human breast cancer cells through inhibition of MAP 
kinase activation through inhibition of expression f 
the RAF-1 gene. 
RAF-1 down-regulation is associated with paclitaxel 




Renal Cell Carcinoma 
Oncogenesis 
RAF-1 is overactivated in conjunction with loss of 








Low RAF-1 kinase activity is significantly associated 
with paclitaxel sensitivity in cervical cancers. 
Ovarian Cancer 
Oncogenesis 
RAF-1 dysregulation is associated with poor prognosis 
and possibly carcinogenesis. RAF-1 inhibition using 
RNAi reduces cellular proliferatin and inhibits ovarian 
tumor cell growth in vitro and in vivo. Similar results 
were observed using antisense oligonucleotide (ASO) 
therapy (ISIS 5132 and ISIS 13650). 
RAF-1 inhibition by the Akt pathway sensitizes human 
ovarian cancer cells to the drug paclitaxel. 
Gastric Cancer 
Oncogenesis 
RAF-1 inactivation using RNAi in gastric cancer cell 
line SGC7901 led to dramatic reductions in 




RAF-1 gene amplification was detected in 4% of 
bladder cancer samples. Deletions at the RAF-1 locus 
were detected in 2.2% of these samples. Both 
amplifications and deletions were heavily correlated 
with high tumor grade (P < 0.00001), advanced stage 
(P < 0.0001), and poor survival (P < 0.05). 
Lymphoma 
Oncogenesis 
RAF-1 is typically over-expressed in thymic 
lymphomas from TCR transgenic mice. 
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